An updated comparison of microarray and RNA-seq for concentration response transcriptomic study: case studies with two cannabinoids, cannabichromene and cannabinol

BMC Genomics, Год журнала: 2025, Номер 26(1)

Опубликована: Апрель 22, 2025

Abstract Background Transcriptomic benchmark concentration (BMC) modeling provides quantitative toxicogenomic information that is increasingly being used in regulatory risk assessment of data poor chemicals. Over the past decade, RNA sequencing (RNA-seq) gradually replacing microarray as major platform for transcriptomic applications due to its higher precision, wider dynamic range, and capability detecting novel transcripts. However, it unclear whether RNA-seq offers substantial advantages over response studies. Results We provide an updated comparison between using two cannabinoids, cannabichromene (CBC) cannabinol (CBN), case The platforms revealed similar overall gene expression patterns with regard both CBC CBN. spite many varieties non-coding transcripts larger numbers differentially expressed genes (DEGs) ranges identified by RNA-seq, displayed equivalent performance identifying functions pathways impacted compound exposure through set enrichment analysis (GSEA). Furthermore, point departure (tPoD) values derived BMC were on same levels Conclusions Considering relatively low cost, smaller size, better availability software public databases interpretation, still a viable method choice traditional such mechanistic pathway identification modeling.

Язык: Английский

---

Acute and prolonged toxicity assessment of Cannabis sativa extract in rodents and lagomorphs

Toxicology Reports, Год журнала: 2025, Номер unknown, С. 101918 - 101918

Опубликована: Янв. 1, 2025

Язык: Английский

---

Comprehensive mini-review: therapeutic potential of cannabigerol – focus on the cardiovascular system

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 26, 2025

Backgrounds Cannabigerol (CBG) is a non-psychoactive phytocannabinoid with broad spectrum of biological effects. However, there still too little research on its safety especially effects the cardiovascular system. Due to agonist alpha-2-adrenergic receptors (α 2 AR), it speculated that may have applications in pharmacotherapy metabolic syndrome, particularly hypertension. Thus, aim our review was analyse therapeutic potential CBG diseases. Methods The based searches PubMed and Web Science databases. Keywords were used identify literature containing mechanistic information Results A shows exhibits hypotensive mice probably through α AR agonism. Other numerous vitro vivo studies show has anti-inflammatory, antioxidant also regulates cell apoptosis. improved tissue sensitivity insulin, showed efficacy inhibiting platelet aggregation. are reports adverse high doses liver architecture function, which calls into question usefulness profile. Conclusion Above mentioned beneficial properties suggest be useful treating hypertension syndrome. lack chronic administration parameters condition, necessary determine need for future other indications.

Язык: Английский

---

Cannabis for medicine and food: A benefit vs risk critical appraisal

South African Journal of Botany, Год журнала: 2024, Номер 175, С. 15 - 31

Опубликована: Окт. 11, 2024

Язык: Английский

---

Safety assessment on CBD-rich hemp extract in sub-chronic cross-sex study with rats

Toxicology and Applied Pharmacology, Год журнала: 2024, Номер 495, С. 117218 - 117218

Опубликована: Дек. 25, 2024

Язык: Английский

---